Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Accumulated Depreciation (2019 - 2026)

Enliven Therapeutics has reported Accumulated Depreciation over the past 8 years, most recently at $243000.0 for Q1 2026.

  • Quarterly results put Accumulated Depreciation at $243000.0 for Q1 2026, down 75.53% from a year ago — trailing twelve months through Mar 2026 was $243000.0 (down 75.53% YoY), and the annual figure for FY2025 was $229000.0, down 75.08%.
  • Accumulated Depreciation reached $243000.0 in Q1 2026 per ELVN's latest filing, up from $229000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $1.1 million in Q3 2025 and bottomed at $229000.0 in Q4 2025.
  • Median Accumulated Depreciation over the past 5 years was $710500.0 (2023), compared with a mean of $691000.0.
  • The largest annual shift saw Accumulated Depreciation surged 79.41% in 2023 before it plummeted 75.53% in 2026.
  • Over 5 years, Accumulated Depreciation stood at $374000.0 in 2022, then surged by 79.41% to $671000.0 in 2023, then surged by 36.96% to $919000.0 in 2024, then plummeted by 75.08% to $229000.0 in 2025, then increased by 6.11% to $243000.0 in 2026.
  • Business Quant data shows Accumulated Depreciation for ELVN at $243000.0 in Q1 2026, $229000.0 in Q4 2025, and $1.1 million in Q3 2025.